Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Gains from Investment Securities (2021 - 2023)

Alx Oncology Holdings' Gains from Investment Securities history spans 3 years, with the latest figure at -$987000.0 for Q4 2023.

  • For Q4 2023, Gains from Investment Securities fell 509.23% year-over-year to -$987000.0; the TTM value through Dec 2023 reached $200000.0, down 17.08%, while the annual FY2025 figure was $929000.0, 12.33% up from the prior year.
  • Gains from Investment Securities for Q4 2023 was -$987000.0 at Alx Oncology Holdings, down from $973000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.1 million in Q4 2021 and bottomed at -$987000.0 in Q4 2023.
  • The 3-year median for Gains from Investment Securities is $174093.5 (2022), against an average of $1.3 million.
  • The largest YoY upside for Gains from Investment Securities was 1.9% in 2023 against a maximum downside of 509.23% in 2023.
  • A 3-year view of Gains from Investment Securities shows it stood at $5.1 million in 2021, then plummeted by 95.3% to $241187.0 in 2022, then tumbled by 509.23% to -$987000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Gains from Investment Securities are -$987000.0 (Q4 2023), $973000.0 (Q3 2023), and $107000.0 (Q2 2023).